Annovis Bio (NYSE:ANVS) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Annovis Bio (NYSE:ANVS – Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08, Zacks reports.

Annovis Bio Stock Performance

NYSE ANVS traded up $0.08 during trading hours on Friday, hitting $0.93. The company had a trading volume of 2,162,279 shares, compared to its average volume of 3,303,590. Annovis Bio has a 1-year low of $0.62 and a 1-year high of $5.50. The company has a market cap of $39.79 million, a PE ratio of -0.52 and a beta of 1.36. The business has a 50 day moving average of $1.10 and a 200-day moving average of $1.82.

Insider Activity

In other news, Director Michael Hoffman acquired 5,000,000 shares of the company’s stock in a transaction on Friday, November 6th. The shares were bought at an average price of $1.00 per share, with a total value of $5,000,000.00. Following the completion of the acquisition, the director owned 8,364,883 shares in the company, valued at $8,364,883. This trade represents a 148.59% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 15.92% of the company’s stock.

Wall Street Analysts Forecast Growth

ANVS has been the subject of a number of research analyst reports. Wall Street Zen raised Annovis Bio from a “strong sell” rating to a “sell” rating in a report on Saturday. Weiss Ratings lowered shares of Annovis Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Canaccord Genuity Group reissued a “buy” rating on shares of Annovis Bio in a report on Tuesday, August 18th. Finally, Roth Capital reduced their price objective on shares of Annovis Bio from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Thursday, August 27th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Annovis Bio currently has a consensus rating of “Hold” and a consensus price target of $12.00.

View Our Latest Report on Annovis Bio

About Annovis Bio

(Get Free Report)

Annovis Bio is a clinical-stage biotechnology company based in Malvern, Pennsylvania. Founded in 2008, the company researches and develops treatments for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease.

Read More

Earnings History for Annovis Bio (NYSE:ANVS)

Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.